The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the UK version of the EU Market Abuse Regulation 596/2014 which is
part of UK law by virtue of the European Union (Withdrawal) Act
2018, as amended and supplemented from time to time. Upon the
publication of this announcement, this inside information is now
considered to be in the public domain.
19
June 2024
IXICO plc
("IXICO" or the
"Company")
New pharma client contract win
valued in excess of £1m for a study of a Parkinsonian
disorder
IXICO plc (AIM: IXI), the precision
analytics company delivering intelligent insights in neuroscience,
is pleased to announce that it has been contracted by a top five
CRO on behalf of a new pharma client to provide its imaging
biomarker services for a Phase 3 clinical trial for patients with a
type of Parkinsonian disorder. The trial is due to run for just
under 5 years and is worth in excess of
£1m.
Giulio Cerroni, Chief Executive
Officer of IXICO, commented:
"Following
the new contract win announced on 23rd May in
Alzheimer's Disease, we are delighted to be announcing the award of
a contract from a new client to support the development of a
promising treatment targeting a Parkinsonian disorder. We are
pleased that our expertise in providing imaging analysis and
radiological reads across clinical trials for a broadening range of
neurodegenerative disorders, is increasingly recognised across the
drug development industry and continues to attract new Sponsors
seeking these expert services."
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks/Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
| |
About
IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More
information is available on www.IXICO.com and
follow us on Twitter @IXICOnews